UCB (OTCMKTS:UCBJY) Shares Cross Above Fifty Day Moving Average – Time to Sell?

UCB SA (OTCMKTS:UCBJY)’s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $144.50 and traded as high as $154.81. UCB shares last traded at $153.55, with a volume of 11,872 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Sunday, October 26th. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

UCB Price Performance

The business’s fifty day moving average price is $144.50 and its 200 day moving average price is $131.98. The company has a quick ratio of 1.01, a current ratio of 1.35 and a debt-to-equity ratio of 0.29.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.